Burden of serious fungal infections in Spain

Clinical Microbiology and Infection

Volumn 21, Issue 2, 2015, Pages 183-189

  Rodriguez Tudela, J L ^a   Alastruey Izquierdo, A ^a,b   Gago, S ^a   Cuenca Estrella, M ^a,b   Leon C ^c   Miro, J M ^d   Nunez Boluda A ^e   Ruiz Camps, I ^f   Sole, A ^g   Denning, D W ^h  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ABPA; Aspergillosis; Burden; Candidiasis; Cryptococcosis; Fungal infections; Histoplasmosis; Mucormycosis; Pneumocystis pneumonia; SAFS

Indexed keywords

ADOLESCENT; ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA; CANDIDEMIA; CRYPTOCOCCAL MENINGITIS; DERMATOMYCOSIS; ESOPHAGUS CANDIDIASIS; FEMALE; HISTOPLASMOSIS; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SENSITIZATION; SPAIN; THRUSH; TRACHEOBRONCHITIS; VAGINA CANDIDIASIS; MIDDLE AGED; MYCOSES; QUESTIONNAIRE; SURVIVAL; YOUNG ADULT;

PNEUMOCYSTIS;

ADOLESCENT; ADULT; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; PREVALENCE; SPAIN; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84923033849     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.07.013     Document Type: Article

References (45)

1. Arendrup M.C., Bruun B., Christensen J.J., Fuursted K., Johansen H.K., Kjaeldgaard P., et al. National surveillance of fungemia in Denmark (2004 to 2009). JClin Microbiol 2011, 49:325-334.
2. Hajjeh R.A., Conn L.A., Stephens D.S., Baughman W., Hamill R., Graviss E., et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. JInfect Dis 1999, 179:449-454.
3. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
4. Denning D.W., Pleuvry A., Cole D.C. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011, 89:864-872.
5. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: human fungal infections. Sci Transl Med 2012, 4:165rv13.
6. Denning D.W., Pleuvry A., Cole D.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013, 51:361-370.
7. Denning D.W., Pleuvry A., Cole D.C. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013, 41:621-626.
8. Foxman B., Muraglia R., Dietz J.P., Sobel J.D., Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. JLow Genit Tract Dis 2013, 17:340-345.
9. Hamers F.F., Downs A.M. The changing face of the HIV epidemic in western Europe: Ware the implications for public health policies?. Lancet 2004, 364:83-94.
10. Registro Nacional de Casos de SIDA Vigilancia epidemiológica del SIDA en España. Sistemas autonómicos de vigilancia epidemiológica Centro Nacional de Epidemiología [Spanish] June 2010, Instituto de Salud Carlos III, Madrid.
11. Esteve A. La contribución de la Cohorte PISCIS a la vigilancia epidemiológica y a la cascada de servicios en Cataluña. XVI Congreso Nacional sobre el Sida Barcelona, Spain; 29 de Septiembre al 2 de Octubre del 2013; Abstract 21.4 2014, SEISIDA, Barcelona.
12. Ambrosioni J., Nicolas D., Aguero F., Manzardo C., Miro J.M. HIV treatment outcomes in Europe and North America: what can we learn from the differences?. Expert Rev Anti Infect Ther 2014, 12:523-526.
13. Caro-Murillo A.M., Castilla J., Perez-Hoyos S., Miro J.M., Podzamczer D., Rubio R., et al. Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results [Spanish]. Enferm Infecc Microbiol Clin 2007, 25:23-31.
14. Rodríguez E., Villarubia S., Díaz O., Hernández G., Tello O. Situación de la tuberculosis en España. Casos de tuberculosis declarados a la red nacional de vigilancia epidemiológica en 2010 [Spanish]. Boletín Epidemiológico Semanal 2012, 20:26-41.
15. Smith N.L., Denning D.W. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011, 37:865-872.
16. Camuset J., Lavole A., Wislez M., Khalil A., Bellocq A., Bazelly B., et al. Bronchopulmonary aspergillosis infections in the non-immunocompromised patient [Spanish]. Rev Pneumol Clin 2007, 63:155-166.
17. Miravitlles M., Soriano J.B., Garcia-Rio F., Munoz L., Duran-Tauleria E., Sanchez G., et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868.
18. Lopez-Campos Bodineau J.L., Fernandez G.J., Lara B.A., Perea-Milla L.E., Moreno L., Cebrian Gallardo J.J., et al. Analysis of admissions for chronic obstructive pulmonary disease in Andalusia in 2000 [Spanish]. Arch Bronconeumol 2002, 38:473-478.
19. OECD iLibrary Health at a glance 2011, OECD Indicators. Avoidable admissions: Respiratory diseases. Available at:. http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2011/avoidable-admissions-respiratory-diseases_health_glance-2011-40-en.
20. Consejería de Sanidad y Servicios Sociales Sistema de vigilancia de factores de riesgo asociados a enfermedades no transmisibles (SIV-FRENT) [French]. Boletín Epidemiológico de la Comunidad de Madrid 1996, 4:3-15.
21. Galán I., Martínez M. Encuesta de Prevalencia de Asma de la Comunidad de Madrid. Documentos Técnicos de Salud Pública Madrid: Dirección General de Salud Pública, Consejería de Salud 1994.
22. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998, 12:315-335.
23. Consejería de Sanidad y Servicios Sociales Documento balance sobre los cinco años de experiencia transcurrida 1992-1996 [Spanish] 1997, Sistema de Comisión Regional de Prevención y Control del Asma, Madrid.
24. To T., Stanojevic S., Moores G., Gershon A.S., Bateman E.D., Cruz A.A., et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012, 12:204.
25. Denning D.W., O'Driscoll B.R., Hogaboam C.M., Bowyer P., Niven R.M. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006, 27:615-626.
26. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
27. Guinea J., Torres-Narbona M., Gijon P., Munoz P., Pozo F., Pelaez T., et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010, 16:870-877.
28. Cahill B.C., Hibbs J.R., Savik K., Juni B.A., Dosland B.M., Edin-Stibbe C., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997, 112:1160-1164.
29. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005, 43(Suppl.1):S267-S270.
30. Gangneux J.P., Camus C., Philippe B. Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients. Rev Mal Respir 2010, 27:e34-46.
31. Herbrecht R., Bories P., Moulin J.C., Ledoux M.P., Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 2012, 1272:23-30.
32. Calderón E.J., Varela J.M., Medrano F.J., Nieto V., Gonzalez-Becerra C., Respaldiza N., et al. Epidemiology of Pneumocystis carinii pneumonia in southern Spain. Clin Microbiol Infect 2004, 10:673-676.
33. Puig-Asensio M., Padilla B., Garnacho-Montero J., Zaragoza O., Aguado J.M., Zaragoza R., et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: A population-based surveillance in Spain. Clin Microbiol Infect 2014, 20:O245-O254.
34. Montravers P., Mira J.P., Gangneux J.P., Leroy O., Lortholary O. Amulticentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 2011, 17:1061-1067.
35. Torres-Narbona M., Guinea J., Martinez-Alarcon J., Munoz P., Gadea I., Bouza E. Impact of zygomycosis on microbiology workload: a survey study in Spain. JClin Microbiol 2007, 45:2051-2053.
36. Buitrago M.J., Cuenca-Estrella M. Current epidemiology and laboratory diagnosis of endemic mycoses in Spain [Spanish]. Enferm Infecc Microbiol Clin 2012, 30:407-413.
37. Matee M.I., Scheutz F., Moshy J. Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis 2000, 6:106-111.
38. Smith E., Orholm M. Trends and patterns of opportunistic diseases in Danish AIDS patients 1980-1990. Scand J Infect Dis 1990, 22:665-672.
39. Buchacz K., Baker R.K., Palella F.J., Chmiel J.S., Lichtenstein K.A., Novak R.M., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: A cohort study. AIDS 2010, 24:1549-1559.
40. Chen J., Yang Q., Huang J., Li L. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study. Int J Med Sci 2013, 10:1625-1631.
41. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. JClin Microbiol 2005, 43:1829-1835.
42. Poikonen E., Lyytikainen O., Anttila V.J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
43. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsaker T., Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. JClin Microbiol 2006, 44:1977-1981.
44. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012, 125(1 Suppl):S3-13.
45. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.